Printer Friendly

Pharsight Corporation Names Arthur Reidel President And Chief Executive Officer; Technology Expert Drives Effort to Deliver Clinical Consulting, Computer-Aided Design Technology to Pharmaceutical Industry.

PALO ALTO, Calif.--(BUSINESS WIRE)--Nov. 25, 1996--Pharsight Corporation, a leading provider of clinical consulting and software solutions to accelerate the drug development process, today announced the appointment of Arthur Reidel as president and chief executive officer.

Reidel co-founded Pharsight Corporation as chairman in 1995, along with Vice President of Marketing Camilla Olson and Vice President of Engineering Greg Lee, Ph.D. Previously, Reidel was president and CEO of Sunrise Test Systems, a leading developer of electronic design automation software.

"We are very fortunate to have someone of Art's stature to head Pharsight Corporation," said Olson. "His reputation in the software industry, as well as his proven management expertise in bringing computer-assisted design solutions to the marketplace, will enable Pharsight Corporation to build a leadership position within our target market of pharmaceutical and biotechnology companies."

"Streamlining clinical trials is the primary challenge researchers face during the lengthy and expensive drug development process," said Reidel. "I am excited about this opportunity to help leading pharmaceutical and biotech companies speed safe, new drugs to market, and to build Pharsight's reputation as a provider of consulting services and software for computer-assisted trial design."

Prior to heading Sunrise Test Systems, Reidel held executive positions with Weitek Corporation, including vice president and general manager of its User Interface Products Division. He has also invested in numerous technology-based companies as a general partner of ABS Ventures Limited Partnerships. Reidel is a graduate of the Massachusetts Institute of Technology and currently serves on the board of directors for the MacNeal Schwendler Corporation.

Pharsight Corporation

Pharsight Corporation, headquartered in Palo Alto, Calif., provides a services-led offering of consulting and software solutions to accelerate drug development and contain time and spending costs within the pharmaceutical industry. Information about Pharsight Corporation is available on the World Wide Web at

CONTACT: Schwartz Communications, Inc.

Cecilia Roach or Jim Owens, 415/512-0770
COPYRIGHT 1996 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1996, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 25, 1996
Previous Article:Connecticut Energy declares dividend.
Next Article:Datametrics Corp. announces completion of $1.85 million financing.

Related Articles
Aspen Technology names Gresham Brebach to board of directors.
Viewlogic Systems promotes Will Herman to president.
Silicon Valley Medical and Software Veterans Team to Form Pharsight Corporation; Software Company Uses Computer-Assisted Trial Design Techniques to...
Pharsight Corporation Names Jaap Mandema Vice President of Scientific Affairs; Pharmaceutical Expert Joins Effort to Help Clinical Researchers...
Pharsight Corporation ships "Virtual Clinical Trials" software to speed drug development; Pharsight trial designer first and only solution developed...
Pharsight Corporation Completes Acquisition of MGA Software's Pharmaceutical Assets; Pharmaceutical Software Powerhouse Results From Business...
Pharsight Names Saeid Akhtari as Vice President of Business Development.
Pharsight Receives Strategic Investment From McKesson HBOC, Inc.
Dr. Terrence Blaschke Joins Pharsight Corporation as Vice President, Collaborative Programs.
Pharsight CEO Arthur Reidel to Present Company Overview at The Wall Street Analyst Forum, February 11, 2002.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters